RExPRT: a machine learning tool to predict pathogenicity of tandem repeat loci.

Authors:
Fazal S; Danzi MC; Xu I; Kobren SN; Sunyaev S and 9 more

Journal:
Genome Biol

Publication Year: 2024

DOI:
10.1186/s13059-024-03171-4

PMCID:
PMC10832122

PMID:
38297326

Journal Information

Full Title: Genome Biol

Abbreviation: Genome Biol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Genetics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"additionally our 120 positive controls dataset (egad00001003562) is available through the european genome-phenome archive [ 35 ]. the scripts to run rexprt for any tr of interest as well as the rexprt scores for the reference trs are available on zenodo [ 36 ] as well as on github at the following url: https://github com/zuchnerlab/rexprt [ 37 ] rexprt is provided under the terms and conditions of the mit open-source license."

Evidence found in paper:

"the scripts to run rexprt for any tr of interest as well as the rexprt scores for the reference trs are available on zenodo [ 36 ] as well as on github at the following url: https://github com/zuchnerlab/rexprt [ 37 ] rexprt is provided under the terms and conditions of the mit open-source license."

Evidence found in paper:

"Declarations Ethics approval and consent to participateAll participants consented for enrollment into the Undiagnosed Diseases Network. Competing interestsE.D. contributed to this work while he was an employee of Illumina, Inc., a public company that develops and markets systems for genetic analysis. The rest of the authors declare that they have no competing interests. Competing interests E.D. contributed to this work while he was an employee of Illumina, Inc., a public company that develops and markets systems for genetic analysis. The rest of the authors declare that they have no competing interests."

Evidence found in paper:

"Funding This work was supported by the American Heart Association predoctoral fellowship awarded to S.F (#917392), the National Institute of Health in grants #2R01NS072248 and #3R01NS072248 to S.Z. and the Muscular Dystrophy Association."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025